FDA/CDC

CDC: New botulism guidelines focus on mass casualty events


 

Treatment

Botulinum antitoxin is the only specific therapy for this infection. If given early – preferably within 24-48 hours of symptom onset – it can stop the progression of paralysis. But antitoxin will not reverse existing paralysis. If paralysis is still progressing outside of that 24- to 48-hour window, the antitoxin should still provide benefit. The antitoxin is available only through state health departments and a request to the CDC.

Botulism antitoxin is made from horse serum and therefore may cause a variety of allergic reactions. The risk for anaphylaxis is less than 2%, far lower than the mortality from untreated botulism.

While these guidelines have an important focus on triaging and treating mass casualties from botulism, it’s important to note that food-borne outbreaks and prevention issues are covered elsewhere on the CDC site.

Dr. Edwards has disclosed no relevant financial relationships. Dr. Adalja is a consultant for Emergent BioSolutions, which makes the heptavalent botulism antitoxin.

Dr. Stone is an infectious disease specialist and author of “Resilience: One Family’s Story of Hope and Triumph Over Evil” and of “Conducting Clinical Research,” the essential guide to the topic. You can find her at drjudystone.com or on Twitter @drjudystone.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Prioritize goals of older patients with multimorbidities, gerontologist says
Journal of Clinical Outcomes Management
Possible obesity effect detected in cancer death rates
Journal of Clinical Outcomes Management
Two treatments show early promise for hypothalamic obesity
Journal of Clinical Outcomes Management
Coffee intake may be driven by cardiovascular symptoms
Journal of Clinical Outcomes Management
Cell phone, smart watch magnets can affect medical devices, FDA says
Journal of Clinical Outcomes Management
FDA preparing an environmental impact statement for 2 sunscreen ingredients
Journal of Clinical Outcomes Management
Healthy lifestyle can reduce dementia risk despite family history
Journal of Clinical Outcomes Management
Physicians’ trust in health care leadership drops in pandemic
Journal of Clinical Outcomes Management
AHA reassures myocarditis rare after COVID vaccination, benefits overwhelm risks
Journal of Clinical Outcomes Management
Benefit from cooling temps for cardiac arrest does not differ in randomized trial
Journal of Clinical Outcomes Management